SOHO State of the Art Updates and Next Questions | The Current State of CAR T-Cell Therapy and Bispecific Antibodies in Mantle Cell Lymphoma.

Autor: Weiss JM; Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI., Phillips TJ; Department of Hematology and Hematopoietic Cell Transplantation, Division of Lymphoma, City of Hope Comprehensive Cancer Center, Duarte, CA. Electronic address: tphillips@coh.org.
Jazyk: angličtina
Zdroj: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Oct 16. Date of Electronic Publication: 2024 Oct 16.
DOI: 10.1016/j.clml.2024.10.009
Abstrakt: MCL remains incurable, and patients who relapse post BTK inhibitors have poor outcomes. BsAbs and CAR T cell therapy are novel strategies to treat patients with R/R MCL. These therapies exhibit favorable outcomes and side effect profiles in a previously dismal space. This review looks to detail the current data available for BsAbs and CAR T cell therapy in R/R MCL, and how are current treatment paradigm is shifting to incorporate these novel agents.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: